期刊文献+

多发性骨髓瘤周围神经病变研究进展 被引量:9

下载PDF
导出
摘要 多发性骨髓瘤(multiple myeloma,MM)是一种常见的浆细胞恶性增殖性疾病,随着硼替佐米和沙利度胺的应用,周围神经病变(peripheral neuropathy,PN)日渐成为一个新的挑战。目前,MM治疗相关性PN发生率约为37%-83%,但发病机制仍不十分明确,主要累及感觉神经,由远到近呈袜套样分布。治疗包括中断药物,调整药物剂量,还可通过改变给药方式来缓解症状。我们回顾分析了新型抗骨髓瘤药物治疗相关性PN的发病率、发病机制、临床表现、危险因素、诊断及治疗。
出处 《临床荟萃》 CAS 2015年第6期710-714,共5页 Clinical Focus
  • 相关文献

参考文献32

二级参考文献72

  • 1安彤同,刘叙仪,方健,吴梅娜.胸腺肽α1治疗化疗所致神经系统副作用的初步研究[J].癌症,2004,23(z1):1428-1430. 被引量:11
  • 2张骏,邓宏宇,巫刚,李双庆.多发性骨髓瘤148例临床分析[J].临床荟萃,2005,20(8):452-454. 被引量:24
  • 3李守静,李宏然,赵相印,李清朗.多发性骨髓瘤诊断的探讨(附2547例分析)[J].中华肿瘤杂志,1995,17(1):43-46. 被引量:151
  • 4Cascinu S.Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer:a randomized,double-blind,placebo-controlled trial.JClin Oncol,2002,20(16):3478-3483.
  • 5Smyth JF.Glutathione reduces thetoxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin:results of a double-blind,randomised trial.Ann Oncol,1997,8(6):569-573.
  • 6韩树桐 武永吉 张之楠 沈悌.多发性骨髓瘤[M].张之楠,沈悌.血液病诊断及疗效标准.第2版[C].北京:科学出版社,1998.373-380.
  • 7韩树桐 武永吉.多发性骨髓瘤[A].张之南.血液学诊断及疗效标准:第2版[C].北京:科学技术出版社,1998.373-379.
  • 8方圻.现代内科学[M].北京:人民军医出版社,1999.2 292~2 299.
  • 9陈灏珠.实用内科学[M].12版.上海:人民卫生出版社.2005:1973-1980.
  • 10Blad6 J, Samaon D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Committee of the EBMT European Group for Blood and Marrow Transplant[J]. Br J Haematol, 1998,102(5) : 1115-1223.

共引文献89

同被引文献68

  • 1谭华,李小刚,罗华,张泽兰,李作孝.以神经系统损害为首发表现的多发性骨髓瘤4例报告[J].中国厂矿医学,2005,18(3):276-276. 被引量:5
  • 2戴虹,潘宇,王晓露.补阳还五汤加味治疗草酸铂化疗后周围神经毒性42例[J].实用中医内科杂志,2006,20(5):518-519. 被引量:16
  • 3Palumbo A,Anderson K.Multiple myeloma[J].N Engl J Med,2011,364:1046-1060.
  • 4Rajkumar SV.Treatment of multiple myeloma[J].Nat Rev Clin Oncol,2011,8:479-491.
  • 5Merin NM,Kelly KR.Clinical use of proteasome inhibitors in treatment of multiple myeloma[J].Pharmaceuticals(Basel),2014,8:1-20.
  • 6Lipchick BC,Fink EE,Nikiforov MA.Oxidative stress and proteasome inhibitors in multiple myeloma[J].Pharmacol Res,2016,105:210-215.
  • 7Knauf W,Tapprich C,Schlag R,et al.Bortezomib-containing regimens are effective in multiple myeloma-results of a non-interventional phaseⅣstudy[J].Oncol Res Treat,2015,38:167-173.
  • 8Chen D,Frezza M,Schmitt S,et al.Bortezomib as the first proteasome inhibitor anticancer drug:current status and future perspectives[J].Curr Cancer Drug Targets,2011,11:239-253.
  • 9San Miguel JF,Schlag R,Khuageva NK,et al.Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma[J].N Engl J Med,2008,359:906-917.
  • 10Harousseau JL,Attal M,Avet-Loiseau H,et al.Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma:results of the IFM 2005-01phase III trial[J].J Clin Oncol,2010,28:4621-4629.

引证文献9

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部